What is metaplastic breast carcinoma?
Metaplastic breast carcinoma (MBC) is a rare and usually aggressive type of breast cancer. It accounts for under 1% of all breast cancers.
The word “metaplastic” means that some of the cancer cells have changed into a different type of cell. Part of the tumour still looks like breast gland tissue, but other parts look like skin-type (squamous) cells, spindle-shaped cells, or even cartilage or bone. Doctors call this mix of appearances “divergent differentiation”.
Most metaplastic breast cancers are triple-negative. This means the cancer cells do not have receptors for oestrogen, progesterone or HER2, so hormone therapy and HER2-targeted drugs do not work. Metaplastic tumours also tend to respond less well to chemotherapy than other triple-negative breast cancers (Aydiner et al., 2015).
MBC often presents as a large, fast-growing lump. Compared with common breast cancers, it spreads to lymph nodes less often but more often travels through the bloodstream to the lungs and brain. Reviews describe it as an aggressive cancer with a less favourable outlook than most breast cancers (Thomas et al., 2023). Treatment combines surgery, chemotherapy and radiotherapy, and newer drugs such as immunotherapy are increasingly used.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Special type of invasive breast carcinoma |
| How common | Rare; about 0.2-1% of breast cancers |
| Typical age | Usually 50-65; median late 50s |
| Sex | Almost always women; very rare in men |
| Receptor status | Triple-negative in about 9 in 10 |
| Typical size at diagnosis | Often larger than 3-4 cm |
| Usual spread | Lungs, bone, brain and liver more than lymph nodes |
| Main treatment | Surgery, chemotherapy, radiotherapy; immunotherapy in selected cases |
| Outlook | Worse than most breast cancers; depends strongly on stage and subtype |
2. Types of metaplastic breast carcinoma
The World Health Organization recognises several subtypes, which behave quite differently.
| Subtype | Description | Behaviour |
|---|---|---|
| Low-grade adenosquamous carcinoma | Small glands and squamous nests in a scar-like background | Low grade; mostly local recurrence |
| Fibromatosis-like metaplastic carcinoma | Bland spindle cells resembling scar tissue | Low grade; can recur locally |
| Squamous cell carcinoma | Skin-type cells, often around a cyst | Aggressive |
| Spindle cell carcinoma | Long, spindle-shaped tumour cells | Aggressive |
| With heterologous mesenchymal differentiation | Areas of cartilage (chondroid), bone (osseous) or other tissue | Aggressive; matrix-producing type may have a somewhat better outlook |
| Mixed metaplastic carcinoma | Combination of the above | Aggressive |
Knowing the subtype matters, because the low-grade forms have a much better outlook than high-grade forms (Khoury, 2023).
3. Causes and risk factors
As with other breast cancers, the exact cause is not known.
| Risk factor | Notes |
|---|---|
| Increasing age | Most patients are past the menopause |
| Female sex | Almost all cases occur in women |
| Inherited BRCA1 variants | Linked with triple-negative breast cancers, including some metaplastic cancers |
| Previous radiation to the chest | A general risk factor for breast cancer |
| Family history | Raises breast cancer risk in general |
Gene changes in the tumour
| Gene change | Approximate frequency | Notes |
|---|---|---|
| TP53 mutation | Common | Linked with high-grade behaviour |
| PIK3CA and PI3K pathway changes | More common than in other triple-negative cancers | A possible drug target |
| Epithelial-mesenchymal transition (EMT) features | Typical | Helps explain the mixed cell types and chemotherapy resistance |
| PD-L1 expression | Present in a proportion | Relevant to immunotherapy |
Why MBC behaves differently
Metaplastic cancer cells have undergone a process called epithelial-mesenchymal transition, in which lining-type cells take on features of connective tissue cells. Cells that have made this change tend to move and invade more easily, resist chemotherapy and spread through the bloodstream rather than the lymph channels. This helps explain the larger tumours, the lower rate of armpit node spread and the higher rate of lung and brain metastases seen in this cancer (Yan, Deng and Zhang, 2024).
4. How does it look
In the breast
| Feature | Description |
|---|---|
| Lump | A firm, well-defined or lobulated mass |
| Size | Often larger than other breast cancers at diagnosis |
| Growth | Can enlarge noticeably over weeks |
| Skin | May become stretched, red or ulcerated over large tumours |
| Cystic areas | Common, especially in squamous types |
On scans
| Scan | Typical findings |
|---|---|
| Mammogram | A round or oval, fairly well-defined mass; calcifications less common |
| Ultrasound | A solid mass, often with cystic or necrotic areas, which can look deceptively benign |
| MRI | A mass with strong rim enhancement and central necrosis |
| CT or PET-CT | Used to check for spread to the lungs, bone and liver |
Because MBC can look round and fairly smooth on scans, it may at first be mistaken for a benign fibroadenoma or a cyst. Any new solid lump in an adult woman should be biopsied.
Under the microscope
| Feature | Description |
|---|---|
| Components | Areas of ordinary breast carcinoma mixed with squamous, spindle, cartilage-like or bone-like tissue |
| Grade | Usually high grade, with many dividing cells and necrosis |
| Receptors | Usually negative for oestrogen, progesterone and HER2 |
| Stains | Keratins (sometimes only patchy) and p63 help confirm that spindle cells are carcinoma, not sarcoma |
5. Symptoms
Common symptoms
- A lump in the breast, often firm and growing quickly
- Change in the size or shape of the breast
- Skin changes, such as redness, dimpling or a sore that does not heal
- Breast pain in some people
- A lump in the armpit, less often than in other breast cancers
Symptoms of spread
| Site | Possible symptoms |
|---|---|
| Lungs | Cough, breathlessness, chest pain |
| Bone | Bone pain, fracture |
| Brain | Headache, sickness, weakness, seizures, confusion |
| Liver | Tummy discomfort, jaundice, weight loss |
When to seek medical advice
See a doctor about any new breast lump, a change in the breast or nipple, or skin changes that do not settle. Breast clinics can usually examine, scan and biopsy a lump on the same day. Do not wait for a routine screening appointment if you notice a change.
6. Diagnosis
| Test | Purpose |
|---|---|
| Clinical examination | Checks the breast and lymph nodes |
| Mammogram and ultrasound | Shows the lump and guides biopsy |
| Core needle biopsy | Confirms cancer and shows the subtype |
| Receptor testing | Oestrogen, progesterone and HER2 status |
| Breast MRI | Measures tumour size and checks the rest of the breast |
| CT chest, abdomen and pelvis, bone scan or PET-CT | Looks for distant spread, often recommended because MBC spreads through the blood |
| Genetic testing | BRCA and other genes, especially for triple-negative cancers |
| PD-L1 and other biomarkers | Guide immunotherapy and targeted treatment |
Diagnostic challenges
Spindle cell types can look very similar to sarcomas or phyllodes tumours. Pathologists use several keratin stains and p63 to show that the cells came from breast lining tissue. A small biopsy may not show every component, so the final subtype is often confirmed after surgery.
Staging
Metaplastic breast cancer is staged in the same way as other breast cancers, using tumour size (T), lymph node involvement (N) and distant spread (M), together with grade and receptor status.
| Stage | Meaning in simple terms |
|---|---|
| Stage I | Small tumour (up to 2 cm), no or minimal node spread |
| Stage II | Tumour 2-5 cm, or a smaller tumour with a few involved nodes |
| Stage III | Large tumour, skin or chest wall involvement, or extensive node spread |
| Stage IV | Spread to distant organs such as lungs, bone, liver or brain |
Because the tumours are often large, many people with MBC are diagnosed at stage II or III.
7. Treatment
Treatment is planned by a breast cancer multidisciplinary team.
Surgery
| Option | Notes |
|---|---|
| Breast-conserving surgery (lumpectomy) | Possible for smaller tumours, followed by radiotherapy |
| Mastectomy | Often needed because tumours are large |
| Sentinel lymph node biopsy | Checks the first nodes draining the breast |
| Axillary clearance | If several nodes contain cancer |
| Breast reconstruction | Immediate or delayed |
Chemotherapy
Chemotherapy is recommended for most high-grade metaplastic cancers. It may be given before surgery (neoadjuvant) to shrink the tumour, or after surgery (adjuvant). Typical regimens include anthracyclines, cyclophosphamide, taxanes and platinum drugs.
MBC is often resistant to standard chemotherapy. In an Istanbul study that matched 54 people with MBC to similar patients with triple-negative ductal cancer, those with metaplastic cancer had clearly worse results at 3 years: about 51% versus 82% were free of progression, and 68% versus 94% were alive (Aydiner et al., 2015). Taxane-containing regimens and radiotherapy were linked with better outcomes in that study. Because responses can be disappointing, teams monitor the tumour closely when chemotherapy is given before surgery, and some prefer surgery first for tumours that can be removed easily.
Radiotherapy
Radiotherapy is given after breast-conserving surgery and after mastectomy for large tumours or node-positive disease. It lowers the risk of the cancer returning in the breast area.
Immunotherapy and targeted treatment
| Treatment | Notes |
|---|---|
| Pembrolizumab with chemotherapy | Standard for high-risk early triple-negative breast cancer; also used for advanced PD-L1-positive disease |
| Sacituzumab govitecan | An antibody-drug conjugate used for advanced triple-negative breast cancer |
| PARP inhibitors (olaparib) | For people with inherited BRCA variants |
| PI3K pathway drugs | Being studied in trials for metaplastic cancers |
| Clinical trials | Recommended where available |
Side effects
| Treatment | Possible side effects |
|---|---|
| Surgery | Pain, wound problems, arm swelling (lymphoedema), numbness |
| Chemotherapy | Hair loss, tiredness, infections, sickness, nerve tingling |
| Radiotherapy | Skin redness, tiredness, breast firmness |
| Immunotherapy | Inflammation of the thyroid, bowel, lungs, liver or skin |
| Antibody-drug conjugates | Low blood counts, diarrhoea, hair loss |
What treatment involves day to day
| Part of treatment | What to expect |
|---|---|
| Surgery | Lumpectomy is often a day case; mastectomy usually means 1-3 nights in hospital |
| Chemotherapy | Treatment every 1-3 weeks for about 4-6 months, given in a day unit |
| Immunotherapy | Infusions every 3-6 weeks, sometimes continued for up to a year |
| Radiotherapy | Weekday sessions for 1-3 weeks with modern short schedules |
8. Outlook (prognosis)
| Situation | General outlook |
|---|---|
| Low-grade subtypes | Good; mainly a risk of local recurrence |
| High-grade, early-stage disease | Many people are cured, but the risk of recurrence is higher than for most breast cancers |
| Large tumours or node-positive disease | Higher risk of spread |
| Metastatic disease | Serious; responses to treatment are often short |
When compared with matched triple-negative breast cancers, MBC has shown shorter survival; in one study, 3-year overall survival was 68% for MBC and 94% for the comparison group (Aydiner et al., 2015). Recurrences usually happen within the first 2-3 years, so the first years of follow-up are the most important.
9. Follow-up
| Follow-up | Purpose |
|---|---|
| Clinic visits every 3-6 months for 2-3 years | Examination and symptom review |
| Yearly mammogram | Checks the treated and other breast |
| Scans if symptoms appear | Look for spread to lungs, bone, liver or brain |
| Management of long-term effects | Heart, bone and nerve health, menopause symptoms |
10. Living with metaplastic breast carcinoma
- Report new symptoms early, especially cough, bone pain or headaches
- Ask about lymphoedema prevention after lymph node surgery
- Keep active, which helps with tiredness and wellbeing
- Ask about genetic testing if not already done
- Consider clinical trials, as research in this rare cancer is active
- Seek support from breast cancer charities, specialist nurses and support groups
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is metaplastic breast cancer the same as triple-negative? | Most are triple-negative, but MBC is a distinct special type |
| Why is it treated differently? | It responds less well to chemotherapy and spreads more often through the blood |
| Will I need hormone therapy? | Usually not, because the cancer lacks hormone receptors |
| Is it inherited? | Usually not, but some patients carry BRCA1 or other variants |
| Can men get it? | Extremely rarely |
| Are low-grade types dangerous? | They rarely spread but can come back in the breast |
12. Questions to ask your care team
- Which subtype of metaplastic carcinoma do I have?
- Is it triple-negative, and what is the PD-L1 result?
- Should I have chemotherapy before or after surgery?
- Would immunotherapy be suitable?
- Should I have genetic testing?
- Are there clinical trials I could join?
Resources
- Aydiner, A. et al. (2015) ‘Metaplastic breast carcinoma versus triple-negative breast cancer: survival and response to treatment’, Medicine, 94(52), e2341.
- Khoury, T. (2023) ‘Metaplastic breast carcinoma revisited; subtypes determine outcomes: comprehensive pathologic, clinical, and molecular review’, Clinics in Laboratory Medicine, 43(2), pp. 221-243.
- Thomas, H.R. et al. (2023) ‘Metaplastic breast cancer: a review’, Critical Reviews in Oncology/Hematology, 182, 103924.
- Yan, Q., Deng, Y. and Zhang, Q. (2024) ‘A comprehensive overview of metaplastic breast cancer: features and treatments’, Cancer Science, 115(8), pp. 2506-2514.
- National Cancer Institute (2026) Breast Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/breast/hp/breast-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.